Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

UniMab

Financiado

Immune privileged immortal myogenic stem cells for gene therapy of Muscular Dy...

Immune privileged immortal myogenic stem cells for gene therapy of Muscular Dystrophy. Duchenne muscular dystrophy (DMD) is a devastating incurable disease, affecting thousands with heavy burden on health systems. This project combines the development of a safe, immune-privileged cell with genetic engineering to cor... ver más

31/12/2025

OSR

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

OSPEDALE SAN RAFFAELE SRL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-05-14

ERC-2019-ADG: ERC Advanced Grant

I+D

Cerrada hace 5 años

0% 100% 100%

2 Participantes

OSR

2.35M€ | Lider

KONTRELMEC

331.26K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2010-18792 GENERATION OF INDUCED PLURIPOTENT STEM CELL LINES FROM MUSCU... 109K€ Cerrado

MABank Creation of a GLP bank of immune-privileged, immortal mesoan... 150K€ Cerrado

i-THYMUS The i-Thymus: wielding the potential of gene therapy, cell t... 4M€ Cerrado

MORBIUS Cure for Miniature Brittle Bones: Treatment of Osteogenesis... 226K€ Cerrado

NOVISTEM NOn-VIral gene modified STEM cell therapy 4M€ Cerrado

SAF2012-39834 TERAPIA CELULAR Y GENICA DIRIGIDA EN ANEMIA DE FANCONI: UN P... 293K€ Cerrado

Duración del proyecto: 67 meses Fecha Inicio: 2020-05-14
Fecha Fin: 2025-12-31

Líder del proyecto

OSPEDALE SAN RAFFAELE SRL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto Duchenne muscular dystrophy (DMD) is a devastating incurable disease, affecting thousands with heavy burden on health systems. This project combines the development of a safe, immune-privileged cell with genetic engineering to correct many dystrophin gene mutations for an efficacious and cost affordable therapy. The applicant pioneered systemic intra-arterial transplantation of mesoangioblasts (blood vessel-derived progenitors) that proved safe in DMD patients and is being implemented for efficacy. However, this personalised approach would prove prohibitively expensive for healthcare systems, as pricing of successful gene therapies is showing. We made the striking observation that human mesoangioblasts can be indefinitely expanded with a novel culture medium, even after genetic manipulation and cloning. Cells will be first genome edited to delete endogenous HLA (β2-microglubin and class II CTA) while inserting tolerogenic HLA-E, fused to β2-microglubin and, as safety device, the Herpes Simplex Thymidine Kinase suicide gene with truncated NGF receptor for selection. Edited clones will be checked for genome integrity. Selected clones will be engineered to express a small nuclear RNA (snRNA) that causes skipping of a given exon of the dystrophin gene. Due to the syncytial nature of muscle fibres, the snRNA also enters and corrects the genetic defect in neighbouring, dystrophic nuclei, thus amplifying of one log the therapeutic effect. Five different cell lines would correct the mutation in 60% of DMD patients. The cell lines will be transplanted in humanized DMD mice and assessed for the ability to escape immune surveillance and to differentiate in dystrophin expressing myofibers, establishing pre-clinical safety and efficacy for an off the shelf, affordable product. The applicant has unique expertise to successfully complete this project, whose strategy may be expanded to other recessive monogenic diseases, for a ground breaking impact in regenerative medicine.

Conecta tu I+D

Entra hoy

¿Olvidó su contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores